Pipeline Moves: Alnylam's Amvuttra approval prospects up after Phase III win [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Meanwhile, Junshi Biosciences's toripalimab saw a Phase II investigator-led ovarian cancer trial suspended. On a positive note, Shiongi's S-309309 reported a Phase II trial completion in obesity. Alnylam win in Phase III ATTR amyloidosis trial Alnylam Pharmaceuticals's Amvuttra (vutrisiran) saw its Likelihood of Approval (LoA) rating increase in familial amyloid cardiomyopathy after a Phase III trial in the same indication met all endpoints. The LoA for Amvuttra shot up by 11 percentage points from 55% to 66% in familial amyloid cardiomyopathy. LoA is calculated by GlobalData's analysis using a combination of machine learning and a proprietary algorithm. LoA can be calculated for a drug by considering characteristics like therapy area, indication and molecule type. A press release from Alnylam Pharmaceuticals, released on 24 June 2024, states that the HELIOS-B trial achieved statistical significance on the primary and all secondary endpoints. GlobalData evaluated the asset
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- BridgeBio granted Perform rating at Oppenheimer on market challenges [Seeking Alpha]Seeking Alpha
- Here's Why You Should Add ALNY Stock to Your Portfolio Right Now [Yahoo! Finance]Yahoo! Finance
- Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund's Performance [Yahoo! Finance]Yahoo! Finance
- Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024Business Wire
ALNY
Earnings
- 8/1/24 - Beat
ALNY
Sec Filings
- 10/3/24 - Form 4
- 10/3/24 - Form 3
- 8/22/24 - Form 4
- ALNY's page on the SEC website